Fluorinated polymeric nanoplatform relieves tumor hypoxia and enhances chemo-sonodynamic therapy
Acta Biomaterialia · 2026-04 · 214 · 527-541
DOI: 10.1016/j.actbio.2026.03.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2026-04. Verfasst von Shanyi Lin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Musculoskeletal Tumor Center, Peking University People's Hospital; School of Materials Science and Engineering; Peking University, Beijing 100871, Ch…. Hauptthemen laut MEDLINE: Tumor Hypoxia, Osteosarcoma, Polymers, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Hypoxia is a hallmark of the solid tumor microenvironment and a key factor limiting therapeutic efficacy in osteosarcoma (OS), as it can promote chemoresistance and impair reactive oxygen species generation during sonodynamic therapy (SDT). Current strategies to alleviate tumor hypoxia, however, remain limited by insufficient endogenous oxygen production and inefficient exogenous oxygen delivery. To address this, we developed a tumor-targeted polymeric nanoplatform designed to relieve hypoxia. An oxygen-delivery system, named PPFCD, was constructed using a fluorine-rich block as an oxygen reservoir and phenylboronic acid side chains for efficient co-loading of doxorubicin (DOX) and chlorin e6 (Ce6). The oxygen carried by the fluorinated segments effectively mitigated intratumoral hypoxia. Upon ultrasound irradiation, PPFCD exhibited a strong sonodynamic effect, which, combined with the high DOX load, led to synergistic chemo-sonodynamic antitumor activity. In an orthotopic OS mouse model, this nanoplatform increased oxygen saturation by ∼10%, inhibited tumor growth by ∼90%, and triggered robust innate and adaptive immune responses. In summary, this study presents a polymeric nanoplatform capable of tumor-specific co-delivery of oxygen and drugs, offering important insights into overcoming the challenges of SDT for solid tumors. STATEMENT OF SIGNIFICANCE: Polymeric Drug Delivery System: A polymeric carrier is employed to co-load an antitumor agent (doxorubicin, DOX), a sonosensitizer (chlorin e6, Ce6), and oxygen, enabling the simultaneous delivery of multiple therapeutic components. Multi-Action Anti-Tumor Platform: The platform incorporates pendant phenylboronic acid (PBA) that enables nitrogen-boron coordination with DOX and hydrophobic interactions with Ce6, together with a fluorine-containing block with high oxygen affinity. Highly Effective Antitumor Activity: The platform elicits strong innate and adaptive immune responses and markedly inhibits osteosarcoma progression, with tumor volumes reduced to approximately 20% of those in the control group. Clinical Application Potential: This platform features a simple formulation, with key components including DOX, Ce6, and polyethylene glycol (PEG), all of which have been approved by the FDA. It demonstrates substantial therapeutic potential in osteosarcoma and shows promising prospects for future clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Musculoskeletal Tumor Center, Peking University People's Hospital; School of Materials Science and Engineering; Peking University, Beijing 100871, China; Department of Orthopedic Surgery, Shanghai Sixth People's Hospita…
- Musculoskeletal Tumor Center, Peking University People's Hospital; School of Materials Science and Engineering; Peking University, Beijing 100871, China.
- Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun 130031, Jilin, China.
- Musculoskeletal Tumor Center, Peking University People's Hospital; School of Materials Science and Engineering; Peking University, Beijing 100871, China. Electronic address: tang15877@163.com.
- Musculoskeletal Tumor Center, Peking University People's Hospital; School of Materials Science and Engineering; Peking University, Beijing 100871, China. Electronic address: tezuka1989@126.com.
- Musculoskeletal Tumor Center, Peking University People's Hospital; School of Materials Science and Engineering; Peking University, Beijing 100871, China. Electronic address: lvshixian@pku.edu.cn.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Beijing Natural Science Foundation
Zitieren
APA
Lin, S., Yang, Z., Yu, B., Jin, G., Lv, L., Wang, L., Liu, L., Zhang, S., Xiang, S., Xiang, X., Su, Y., Bi, Z., Wu, S., Tang, X., Guo, Y., & Lv, S. (2026). Fluorinated polymeric nanoplatform relieves tumor hypoxia and enhances chemo-sonodynamic therapy. Acta Biomaterialia, 214, 527-541. https://doi.org/10.1016/j.actbio.2026.03.008
Vancouver
Lin S, Yang Z, Yu B, Jin G, Lv L, Wang L, et al. Fluorinated polymeric nanoplatform relieves tumor hypoxia and enhances chemo-sonodynamic therapy. Acta Biomaterialia. 2026;214:527-541. doi:10.1016/j.actbio.2026.03.008
BibTeX
@article{Lin2026,
author = {Lin, Shanyi and Yang, Zhaofan and Yu, Bingzheng and Jin, Guanyu and Lv, Letian and Wang, Luyao and Liu, Linlin and Zhang, Shucheng and Xiang, Sijun and Xiang, Xinyu and Su, Yuanzhen and Bi, Zhuoling and Wu, Shuilin and Tang, Xiaodong and Guo, Yu and Lv, Shixian},
title = {Fluorinated polymeric nanoplatform relieves tumor hypoxia and enhances chemo-sonodynamic therapy},
journal = {Acta Biomaterialia},
year = {2026},
volume = {214},
pages = {527--541},
doi = {10.1016/j.actbio.2026.03.008}
}
EUVIMED